[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-336559-en":3,"doc-seo-336559-105":50,"detail-sidebar-cat-0-en-105":115},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":20,"is_deleted":4,"is_public":21,"is_downloadable":21,"audit_status":21,"page_count":11,"language":22,"language_code":23,"site_id":24,"html_lang":23,"table_of_contents":25,"faqs":26,"seo_title":27,"seo_description":14,"update_tm":28,"read_time":29,"preview_page_count":30,"preview_urls":31},336559,8796095461610,"Oliver","https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c",8,"Research & Report","The contribution of second primary cancers to the mortality of patients with a first primary breast cancer","Second primary cancers (SPCs) are estimated to affect nearly 5% of patients within 10 years after breast cancer diagnosis. A population-based cohort study followed 17,210 patients with a breast first primary cancer (FPC) diagnosed between 2000 and 2010, tracking SPC occurrence through 31/12/2015 and vital status through 30/06/2021. SPC patients showed higher death hazards, with 15-year cumulative mortality reaching 59.5% for synchronous and 68.7% for metachronous SPCs, versus 43.6% and 44.8% for FPC only.","Breast Cancer Research and Treatment (2024) 207:323–330  \n[https://doi.org/10.1007/s10549-024-07361-3](https://doi.org/10.1007/s10549-024-07361-3)  \nThe contribution of second primary cancers to the mortality of patients with a first primary breast cancer  \nElisabete Gonçalves1,2 · Filipa Fontes1,2,3,4 · Jéssica Rocha Rodrigues5,6 · Rita Calisto5,6 · Maria José Bento5,6,7 · Nuno Lunet1,2,3 · Samantha Morais1,2  \nReceived: 9 January 2024 / Accepted: 24 April 2024 / Published online: 13 June 2024 © The Author(s) 2024  \nAbstract  \nPurpose Second primary cancers (SPCs) are estimated to affect nearly 5% of patients with breast cancer within 10 years of their diagnosis. This study aimed to estimate the contribution of SPCs to the mortality of patients with a breast first primary cancer (FPC) .  \nMethods A population-based cohort of 17,210 patients with a breast FPC diagnosed between 2000 and 2010 was followed for SPCs (31/12/2015) and vital status (30/06/2021). Patients diagnosed with an SPC (265 synchronous and 897 metachronous, ≤ 1 and > 1 year after the FPC, respectively) were matched (1:3, by five-year age group and year of breast FPC diagnosis) to those without an SPC and alive when the corresponding SPC was diagnosed.  \nResults Significantly higher hazards of death were found among patients with an SPC [hazard ratio of 1.56, 95% confidence interval (CI) 1.29–1.89 for synchronous SPCs; and 2.85, 95%CI 2.56–3.17 for metachronous SPCs] compared to patients with a breast FPC only. Estimates were higher for synchronous lung, stomach, non-Hodgkin lymphoma and breast SPCs, and metachronous liver, stomach, ovary, lung, rectum, corpus uteri, colon, breast, and non-Hodgkin lymphoma SPCs. The 15-year cumulative mortality was 59.5% for synchronous SPCs and 68.7% for metachronous SPCs, which was higher than in patients with a breast FPC only (43.6% and 44.8%, respectively) .  \nConclusions In Northern Portugal, patients with an SPC following a breast FPC have a higher mortality compared with patients with a breast FPC only.  \nKeywords Breast neoplasms · Epidemiology · Population register · Mortality · Second primary neoplasm  \nAbbreviations  \n95%CI 95% Confidence interval  \nFPC First primary cancer  \n* Samantha Morais [samantha.morais@ispup.up.pt](samantha.morais@ispup.up.pt)  \n1 EPIUnit – Instituto de Saúde Pública, Universidade do Porto, Rua das Taipas 135, 4050-091 Porto, Portugal  \n2 Laboratório Para a Investigação Integrativa e Translacionalem Saúde Populacional (ITR), Porto, Portugal  \n3 Departamento de Ciências da Saúde Pública e Forenses e Educação Médica, Faculdade de Medicina da Universidadedo Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal  \n4 Unidade de Investigação em Enfermagem OncológicaCentro de Investigação (CI-IPOP) & Porto Comprehensive Cancer Center (Porto.CCC) & RISE@CI-IPOP (Rede de Investigação em Saúde), Instituto Português de Oncologia do Porto FG, EPE (IPO-Porto), Rua Dr. António Bernardino de Almeida 865, 4200-072 Porto, Portugal  \nHR Hazards ratio  \nIACR International Association of Cancer Registries  \nIARC International Agency for Research on Cancer  \n5 Grupo de Investigação em Epidemiologia, Resultados, Economia e Gestão em Oncologia-Centro de Investigação (CI-IPOP) & Porto Comprehensive Cancer Center (Porto.CCC) & RISE@CI-IPOP (Rede de Investigação em Saúde), Instituto Português de Oncologia do Porto FG, EPE (IPO-Porto), Porto, Portugal  \n6 Serviço de Epidemiologia, Instituto Português de Oncologia do Porto FG, EPE (IPO-Porto), Porto, Portugal  \n7 Departamento de Estudos de Populações, ICBAS-Instituto de Ciências Biomédicas Abel Salazar da Universidadedo Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal  \nRD  \nRR RORENOSPC  \nUSA  \nRisk difference  \nRelative risk  \nNorth Region Cancer Registry of Portugal Second primary cancer  \nUnited States of America  \nIntroduction  \nBreast cancer is the most incident cancer worldwide, accounting for 2.3 million new cancer cases in 2020. ","cbCaitvByHLnSKrT","https://ap.wps.com/l/cbCaitvByHLnSKrT","pdf",704219,11,1,"English","en",105,"# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What was the study purpose regarding second primary cancers (SPCs)?\",\"answer\":\"To estimate how SPCs contribute to mortality among patients who have a breast first primary cancer (FPC).\"},{\"question\":\"How was the cohort constructed and followed in the study?\",\"answer\":\"A population-based cohort of 17,210 breast FPC patients diagnosed from 2000 to 2010 was followed for SPC development and vital status through the specified 2015 and 2021 dates.\"},{\"question\":\"What did the study find about mortality for synchronous versus metachronous SPCs?\",\"answer\":\"Patients with an SPC had higher hazards of death than patients with breast FPC only; 15-year cumulative mortality was 59.5% for synchronous SPCs and 68.7% for metachronous SPCs.\"}]","The contribution of second primary cancers to the mortality of patients with a first primary breast cancer | PDF",1790015604,20,4,[32,36,41,46],{"page_no":21,"url":33,"width":34,"height":35},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d4515a5283aa56cf4dc236e47c5da011.webp",983,1305,{"page_no":37,"url":38,"width":39,"height":40},2,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d5ce9405416c17e96a980e5302cd7d6e.webp",982,1304,{"page_no":42,"url":43,"width":44,"height":45},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3859cbbf097a1c488acb05b21a8edc4a.webp",981,1303,{"page_no":30,"url":47,"width":48,"height":49},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0c7004fbaefd667ef52a27b2d7a74dfa.webp",980,1301,{"code":4,"msg":51,"data":52},"ok",{"site_id":24,"language":23,"slug":53,"title":13,"keywords":54,"description":14,"schema_data":55,"social_meta":109,"head_meta":111,"extra_data":113,"updated_unix":114},"the-contribution-of-second-primary-cancers-to-the-mortality-of-patients-with-a-first-primary-breast-cancer","",{"@graph":56,"@context":108},[57,71,91],{"@type":58,"itemListElement":59},"BreadcrumbList",[60,64,67,69],{"item":61,"name":62,"@type":63,"position":21},"https://docshare.wps.com","Home","ListItem",{"item":65,"name":66,"@type":63,"position":37},"https://docshare.wps.com/document/","Document",{"item":68,"name":12,"@type":63,"position":42},"https://docshare.wps.com/document/research-report/",{"item":70,"name":13,"@type":63,"position":30},"https://docshare.wps.com/document/the-contribution-of-second-primary-cancers-to-the-mortality-of-patients-with-a-first-primary-breast-cancer/336559/",{"url":70,"name":13,"@type":72,"image":73,"author":78,"headline":13,"publisher":80,"fileFormat":83,"inLanguage":23,"description":14,"dateModified":84,"datePublished":85,"encodingFormat":83,"isAccessibleForFree":86,"interactionStatistic":87},"DigitalDocument",{"url":74,"@type":75,"width":76,"height":77},"https://docshare.wps.com/thumbnails/the-contribution-of-second-primary-cancers-to-the-mortality-of-patients-with-a-first-primary-breast-cancer/336559.png","ImageObject",300,407,{"name":9,"@type":79},"Person",{"url":61,"name":81,"@type":82},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":88,"interactionType":89,"userInteractionCount":20},"InteractionCounter",{"@type":90},"ViewAction",{"@type":92,"mainEntity":93},"FAQPage",[94,100,104],{"name":95,"@type":96,"acceptedAnswer":97},"What was the study purpose regarding second primary cancers (SPCs)?","Question",{"text":98,"@type":99},"To estimate how SPCs contribute to mortality among patients who have a breast first primary cancer (FPC).","Answer",{"name":101,"@type":96,"acceptedAnswer":102},"How was the cohort constructed and followed in the study?",{"text":103,"@type":99},"A population-based cohort of 17,210 breast FPC patients diagnosed from 2000 to 2010 was followed for SPC development and vital status through the specified 2015 and 2021 dates.",{"name":105,"@type":96,"acceptedAnswer":106},"What did the study find about mortality for synchronous versus metachronous SPCs?",{"text":107,"@type":99},"Patients with an SPC had higher hazards of death than patients with breast FPC only; 15-year cumulative mortality was 59.5% for synchronous SPCs and 68.7% for metachronous SPCs.","https://schema.org",{"og:url":70,"og:type":110,"og:title":13,"og:site_name":81,"og:description":14},"article",{"robots":112,"canonical":70},"index,follow",{"doc_id":7,"site_id":24},1790092992,{"code":4,"msg":5,"data":116},[117,121,125,129,134,139,144,147,151,154,158],{"id":21,"doc_module":4,"doc_module_name":66,"category_name":118,"show_sort_weight":119,"slug":120},"Story & Novel",90,"story-novel",{"id":37,"doc_module":4,"doc_module_name":66,"category_name":122,"show_sort_weight":123,"slug":124},"Literature",80,"literature",{"id":30,"doc_module":4,"doc_module_name":66,"category_name":126,"show_sort_weight":127,"slug":128},"Exam",70,"exam",{"id":130,"doc_module":4,"doc_module_name":66,"category_name":131,"show_sort_weight":132,"slug":133},5,"Comic",60,"comic",{"id":135,"doc_module":4,"doc_module_name":66,"category_name":136,"show_sort_weight":137,"slug":138},6,"Technology",50,"technology",{"id":140,"doc_module":4,"doc_module_name":66,"category_name":141,"show_sort_weight":142,"slug":143},7,"Healthcare",40,"healthcare",{"id":11,"doc_module":4,"doc_module_name":66,"category_name":12,"show_sort_weight":145,"slug":146},30,"research-report",{"id":148,"doc_module":4,"doc_module_name":66,"category_name":149,"show_sort_weight":29,"slug":150},9,"Religion & Spirituality","religion-spirituality",{"id":29,"doc_module":4,"doc_module_name":66,"category_name":152,"show_sort_weight":29,"slug":153},"World Cup","world-cup",{"id":155,"doc_module":4,"doc_module_name":66,"category_name":156,"show_sort_weight":155,"slug":157},10,"Lifestyle","lifestyle",{"id":159,"doc_module":4,"doc_module_name":66,"category_name":160,"show_sort_weight":130,"slug":161},19,"General","general"]